

## Výpis všetkých citácií na publikácie typu ADC

(poradie jednotlivých ADC publikácií autora korešponduje s rešeršou z UK TU v Trnave)

### ADC2

Samec, M., Liskova, A., Kubatka, P., Uramova, S., Zubor, P., Samuel, S. M., ... & Kudela, E. (2019). The role of dietary phytochemicals in the carcinogenesis via the modulation of miRNA expression. *Journal of cancer research and clinical oncology*, 1-15.

cit: Jasek, K., Kubatka, P., Samec, M., Liskova, A., Smejkal, K., Vybohova, D., ... & Danko, J. (2019). DNA Methylation Status in Cancer Disease: Modulations by Plant-Derived Natural Compounds and Dietary Interventions. *Biomolecules*, 9(7), 289.

### ADC 3

Evaluating bococizumab, a monoclonal antibody to PCSK9, on lipid levels and clinical events in broad patient groups with and without prior cardiovascular events : Rationale and design of the Studies of PCSK9 Inhibition and the Reduction of vascular Events (SPIRE) Lipid Lowering and SPIRE Cardiovascular Outcomes Trials / Paul M. Ridker, Pierre Amarenco, Robert Brunell, Robert J. Glynn, J. Wouter Jukema, ... Jozef Beňačka et al..

[HTMLJ Evaluating bococizumab, a monoclonal antibody to PCSK9, on lipid levels and clinical events in broad patient groups with and without prior cardiovascular ...](#)

[PM Ridker, P Amarenco, R Brunell, RJ Glynn... - American heart ...](#), 2016 - Elsevier

Background Although statins significantly reduce vascular event rates, residual cholesterol risk remains high in many patient groups, including those with known vascular disease as well as in the setting of high-risk primary prevention. Bococizumab is a humanized monoclonal antibody that inhibits proprotein convertase subtilisin-kexin type 9 (PCSK9), prolongs the half-life of hepatic low-density lipoprotein (LDL) receptors, and reduces circulating atherogenic cholesterol levels. Design The SPIRE program comprises 6 lipid ...

☆ 99 Citované 45-krát Súvisiace články Všetky verzie 10

### ADC4

Relationship of C-reactive protein reduction to cardiovascular event reduction following treatment with canakinumab : a secondary analysis from the CANTOS randomised controlled trial / Paul M. Ridker, Jean G. MacFadyen, Brendan M. Everett, Peter Libby, Tom Thuren, ... Jozef Beňačka et al..

[Relationship of C-reactive protein reduction to cardiovascular event reduction following treatment with canakinumab: a secondary analysis from the CANTOS ...](#)

[PM Ridker, JG MacFadyen, BM Everett, P Libby... - The Lancet](#), 2018 - Elsevier

Background Canakinumab, a monoclonal antibody targeting interleukin-1 $\beta$ , reduces inflammation and cardiovascular event rates with no effect on lipid concentrations. However, it is uncertain which patient groups benefit the most from treatment and whether reductions in the inflammatory biomarker high-sensitivity C-reactive protein (hsCRP) correlate with clinical benefits for individual patients. Methods The Canakinumab Anti-Inflammatory Thrombosis Outcomes Study (CANTOS) used computer-generated codes to randomly ...

☆ 99 Citované 231-krát Súvisiace články Všetky verzie 9

### ADC5

Rationale, design, and baseline characteristics of the CLARIFY registry of outpatients with stable coronary artery disease / Emmanuel Sorbets, Nicola Greenlaw, Roberto Ferrari, Ian Ford, Kim M. Fox, ... Jozef Beňačka et al..

[Rationale, design, and baseline characteristics of the CLARIFY registry of outpatients with stable coronary artery disease](#)

[E Sorbets, N Greenlaw, R Ferrari, I Ford... - Clinical ...](#), 2017 - Wiley Online Library

Background Despite major advances in prevention and treatment, coronary artery disease (CAD) remains the leading cause of death worldwide. Whereas many sources of data are available on the epidemiology of acute coronary syndromes, fewer datasets reflect the contemporary management and outcomes of stable CAD patients. Hypothesis A worldwide contemporary registry would improve our knowledge about stable CAD. The main objectives are to describe the demographics, clinical profile, contemporary management and outcomes ...

☆ 99 Citované 9-krát Súvisiace články Všetky verzie 10

## ADC6

Prevalence of Anginal Symptoms and Myocardial Ischemia and Their Effect on Clinical Outcomes in Outpatients With Stable Coronary Artery Disease Data From the International Observational CLARIFY Registry / Philippe Gabriel Steg, Nicola Greenlaw, Michal Tendera, Jean-Claude Tardif, Roberto Ferrari, ... Jozef Beňačka et al..

In: JAMA internal medicine. - ISSN 2168-6106. - Vol. 174, Issue 10 (2014), s. 1651-1659.

[Prevalence of anginal symptoms and myocardial ischemia and their effect on clinical outcomes in outpatients with stable coronary artery disease: data from the ...](#)

[PG Steg, N Greenlaw, M Tendera, JC Tardif... - JAMA internal ..., 2014 - jamanetwork.com](#)

Importance In the era of widespread revascularization and effective antianginals, the prevalence and prognostic effect of anginal symptoms and myocardial ischemia among patients with stable coronary artery disease (CAD) are unknown. Objective To describe the current clinical patterns among patients with stable CAD and the association of anginal symptoms or myocardial ischemia with clinical outcomes. Design, Setting, and Participants The Prospective Observational Longitudinal Registry of Patients With Stable Coronary Artery ...

☆ [📄](#) Citované 57-krát [Súvisiace články](#) [Všetky verzie 9](#)

## ADC7

Randomized Study of Antihypertensive Efficacy and Safety of Combination Aliskiren/Valsartan vs Valsartan Monotherapy in Hypertensive Participants With Type 2 Diabetes Mellitus / George L. Bakris, Suzanne Oparil, Das Purkayastha, Anthony M. Yadao, Thomas Alessi, James R. Sowers,... Jozef Beňačka et al..

In: Journal of clinical hypertension. - ISSN 1524-6175. - Vol. 15, Issue 2 (2013), s. 92-100.

[Randomized study of antihypertensive efficacy and safety of combination aliskiren/valsartan vs valsartan monotherapy in hypertensive participants with type 2 ...](#)

[GL Bakris, S Oparil, D Purkayastha... - The Journal of ..., 2013 - Wiley Online Library](#)

In this double-blind study, 1143 hypertensive participants with type 2 diabetes and stage 1 or 2 chronic kidney disease (CKD) were randomized to receive combination aliskiren/valsartan 150/160 mg or valsartan 160 mg monotherapy for 2 weeks, with force-titration to 300/320 mg and 320 mg, respectively, for another 6 weeks. Ambulatory blood pressure (ABP), the primary outcome, was available for 665 participants. Reductions from baseline to week 8 in 24-hour ABP were -14.1/-8.7 mm Hg with aliskiren/valsartan vs ...

☆ [📄](#) Citované 21-krát [Súvisiace články](#) [Všetky verzie 6](#)

## ADC8

Bradycardia and atrial fibrillation in patients with stable coronary artery disease treated with ivabradine : an analysis from the SIGNIFY study / Kim M. Fox, Ian Ford, Philippe Gabriel Steg, Jean-Claude Tardif, Michal Tendera, Roberto Ferrari,... Jozef Beňačka et al..

[Bradycardia and atrial fibrillation in patients with stable coronary artery disease treated with ivabradine: an analysis from the SIGNIFY study](#)

[K Fox, I Ford, PG Steg, JC Tardif... - European heart ..., 2015 - academic.oup.com](#)

Aim The aim of this study was to determine the impact of emergent bradycardia and atrial fibrillation (AF) on cardiovascular outcomes in 19 083 patients with stable coronary artery disease (CAD) receiving ivabradine or placebo (SIGNIFY, Study assessInG the morbidity-mortality benefits of the If inhibitor ivabradine in patients with coronary artery disease).

Methods and results Emergent bradycardia (resting heart rate < 50 bpm on 12-lead electrocardiogram) with ivabradine was reported in 3572 patients (37.4%) overall, and in ...

☆ [📄](#) Citované 28-krát [Súvisiace články](#) [Všetky verzie 10](#)

## ADC9

Reduction in Ischemic Events With Ticagrelor in Diabetic Patients With Prior Myocardial Infarction in PEGASUS-TIMI 54 / Deepak L. Bhatt, Marc P. Bonaca, Sameer Bansilal, Dominick J. Angiolillo, Marc Cohen, ... Jozef Beňačka et al..

In: Journal of the american college of cardiology. - ISSN 0735-1097. - Vol. 67, Issue 23 (2016), s. 2732-2740.

### [Reduction in ischemic events with ticagrelor in diabetic patients with prior myocardial infarction in PEGASUS–TIMI 54](#)

[DL Bhatt, MP Bonaca, S Bansilal...](#) - Journal of the ..., 2016 - onlinejacc.org

Background Patients with diabetes appear to be at elevated risk of atherothrombotic events. Objectives The purpose of this study was to determine the effect of antiplatelet therapy with ticagrelor on recurrent ischemic events in patients with diabetes and prior myocardial infarction (MI). Methods We examined the subgroups of patients with diabetes (n= 6,806) and without diabetes (n= 14,355) from PEGASUS–TIMI 54 (Prevention of Cardiovascular Events in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a ...

☆ [🔗](#) Citované 110-krát [Súvisiace články](#) [Všetky verzie 10](#)

## ADC10

Aliskiren, Enalapril, or Aliskiren and Enalapril in Heart Failure / John J.V. McMurray, Henry Krum, William T. Abraham, Kenneth Dickstein, ... Jozef Beňačka et al..

In: The New England Journal of Medicine. - ISSN 0028-4793. - Vol. 374, Issue 16 (2016), s. 1521-1532.

### [\[HTML\] Aliskiren, enalapril, or aliskiren and enalapril in heart failure](#)

[JJV McMurray, H Krum, WT Abraham...](#) - ... England Journal of ..., 2016 - Mass Medical Soc

Background Among patients with chronic heart failure, angiotensin-converting–enzyme (ACE) inhibitors reduce mortality and hospitalization, but the role of a renin inhibitor in such patients is unknown. We compared the ACE inhibitor enalapril with the renin inhibitor aliskiren (to test superiority or at least noninferiority) and with the combination of the two treatments (to test superiority) in patients with heart failure and a reduced ejection fraction. Methods After a single-blind run-in period, we assigned patients, in a double-blind fashion ...

☆ [🔗](#) Citované 130-krát [Súvisiace články](#) [Všetky verzie 15](#)

Nadri, G., Saxena, S., Stefanickova, J., Ziak, P., Benacka, J., Gilhotra, J. S., & Kruzliak, P. (2019). Disorganization of retinal inner layers correlates with ellipsoid zone disruption and retinal nerve fiber layer thinning in diabetic retinopathy. *Journal of Diabetes and its Complications*.

cit: Kołodziej, M., Waszczykowska, A., Korzeniewska-Dyl, I., Pyziak-Skupien, A., Walczak, K., Moczulski, D., ... & Zmysłowska, A. (2019). The HD-OCT Study May Be Useful in Searching for Markers of Preclinical Stage of Diabetic Retinopathy in Patients with Type 1 Diabetes. *Diagnostics*, 9(3), 105.

**SPOLU 633 citáciei evidovaných v rôznych databázach na publikácie typu ADC, z toho 414 v databáze WoS (vid' príloha).**

**Príloha: Výpis-zoznam citácií z databázy WoS na jednotlivé ADC publikácie. Zoznamy sú súčasťou prílohovej časti habilitačného spisu**

**Výpis citácií na ostatné publikácie (okrem ADC publikácií uvedených vyššie).  
Citujúce práce sa nachádzajú v citačnej rešerši z UK TU v Trnave**

**Citujúce dokumenty:**

COLLADO, S. et al. Serum osteoprotegerin in prevalent hemodialysis patients : associations with mortality, atherosclerosis and cardiac function. In BMC Nephrology, volume 18, issue 1, 2017, article number 290. ISSN 1471-2369.

WOS SCOPUS PubMed

RORTH, R. et al. Risk of Incident Heart Failure in Patients With Diabetes and Asymptomatic Left Ventricular Systolic Dysfunction. In Diabetes care, vol. 41, issue 6, 2018, s. 1285-1291. ISSN 0149-5992.

WOS SCOPUS EBSCO PubMed Medline

CHAE S. Z. Et al.: The Correlation of Serum Osteoprotegerin with Non-Traditional Cardiovascular Risk Factors and Arterial Stiffness in Patients with Pre-Dialysis Chronic Kidney Disease: Results from the KNOW-CKD Study. In *Journal of Korean Medical Science*, 2018, 33 (53).

Medline PubMed SCOPUS

**Citovaný dokument:**

Kruzliak P, Berezin A, Kremzer A, Samura T, Benacka J, Mozos I, et al. Global longitudinal strain and strain rate in type two diabetes patients with chronic heart failure: relevance to osteoprotegerin. *Folia Med (Plovdiv)* 2016;58(3):164–173.

BIELIK, J. Brušná ultrasonografia na Slovensku v rokoch 1991 až 2000. In *Lekársky obzor*, roč. 51, č. 7, 2002, s. 221-223. ISSN 0457-4214.

SCOPUS (2x)

ŘEZANINOVÁ, J. - HRAZDIRA, L. - MOC KRÁLOVÁ, D. Ultrasonografické zobrazení muskuloskeletálních poranění ve sportu z pohledu fyzioterapeuta. In *Medicina Sportiva Bohemica & Slovaca*, vol. 25, no. 4, 2016, s. 150-156. ISSN 1210-5481.

EBSCO